122 related articles for article (PubMed ID: 14527550)
21. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
Prevost GP; Pradines A; Brezak MC; Lonchampt MO; Viossat I; Ader I; Toulas C; Kasprzyk P; Gordon T; Favre G; Morgan B
Int J Cancer; 2001 Mar; 91(5):718-22. PubMed ID: 11267986
[TBL] [Abstract][Full Text] [Related]
24. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
Le Diguarher T; Ortuno JC; Shanks D; Guilbaud N; Pierré A; Raimbaud E; Fauchère JL; Hickman JA; Tucker GC; Casara PJ
Bioorg Med Chem Lett; 2004 Feb; 14(3):767-71. PubMed ID: 14741286
[TBL] [Abstract][Full Text] [Related]
27. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.
Andela VB; Rosenblatt JD; Schwarz EM; Puzas EJ; O'Keefe RJ; Rosier RN
Clin Orthop Relat Res; 2002 Apr; (397):228-39. PubMed ID: 11953614
[TBL] [Abstract][Full Text] [Related]
28. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
Ganguly AK; Doll RJ; Girijavallabhan VM
Curr Med Chem; 2001 Oct; 8(12):1419-36. PubMed ID: 11562275
[TBL] [Abstract][Full Text] [Related]
29. Actinoplanic acids A and B as novel inhibitors of farnesyl-protein transferase.
Silverman KC; Cascales C; Genilloud O; Sigmund JM; Gartner SE; Koch GE; Gagliardi MM; Heimbuch BK; Nallin-Omstead M; Sanchez M
Appl Microbiol Biotechnol; 1995; 43(4):610-6. PubMed ID: 7546601
[TBL] [Abstract][Full Text] [Related]
30. Costunolide, a sesquiterpene from the stem bark of Magnolia sieboldii, inhibits the RAS-farnesyl-proteintransferase.
Park SH; Choi SU; Lee CO; Yoo SE; Yoon SK; Kim YK; Ryu SY
Planta Med; 2001 Jun; 67(4):358-9. PubMed ID: 11458455
[TBL] [Abstract][Full Text] [Related]
31. Farnesyl protein transferase inhibitory components of Polygonum multiflorum.
Kwon BM; Kim SH; Baek NI; Lee SI; Kim EJ; Yang JH; Chae BS; Lee JH; Park HW; Park JS; Kim DK
Arch Pharm Res; 2009 Apr; 32(4):495-9. PubMed ID: 19407965
[TBL] [Abstract][Full Text] [Related]
32. Farnesyltransferase inhibitors. Preclinical development.
Kohl NE
Ann N Y Acad Sci; 1999; 886():91-102. PubMed ID: 10667207
[TBL] [Abstract][Full Text] [Related]
33. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
[TBL] [Abstract][Full Text] [Related]
34. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic.
Scholten JD; Zimmerman K; Oxender M; Sebolt-Leopold J; Gowan R; Leonard D; Hupe DJ
Bioorg Med Chem; 1996 Sep; 4(9):1537-43. PubMed ID: 8894110
[TBL] [Abstract][Full Text] [Related]
36. Parallel liquid synthesis of N,N'-Disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors.
Le Diguarher T; Ortuno JC; Dorey G; Shanks D; Guilbaud N; Pierré A; Fauchère JL; Hickman JA; Tucker GC; Casara PJ
Bioorg Med Chem; 2003 Jul; 11(14):3193-204. PubMed ID: 12818682
[TBL] [Abstract][Full Text] [Related]
37. Relationship between flavonoid structure and inhibition of farnesyl protein transferase.
Kang HM; Kim JH; Lee MY; Son KH; Yang DC; Baek NI; Kwon BM
Nat Prod Res; 2004 Aug; 18(4):349-56. PubMed ID: 15214488
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
Kohl NE; Koblan KS; Omer CA; Oliff A; Gibbs JB
Methods Mol Biol; 1998; 84():283-91. PubMed ID: 9666457
[TBL] [Abstract][Full Text] [Related]
39. Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases.
Omer CA; Kral AM; Diehl RE; Prendergast GC; Powers S; Allen CM; Gibbs JB; Kohl NE
Biochemistry; 1993 May; 32(19):5167-76. PubMed ID: 8494894
[TBL] [Abstract][Full Text] [Related]
40. Farnesyl transferase inhibitors as anticancer agents.
Haluska P; Dy GK; Adjei AA
Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
